Impact of Intravenous Lidocaine, Dexmedetomidine, and Intrathecal Morphine on Metastasis-Related Biomarkers and Cellular Immune Profiles in Colorectal Surgery: A Prospective, Randomized Controlled Trial.
Jeayoun Kim, Seungwon Lee, Eun Jung Oh et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, randomized controlled trial evaluated the effects of intravenous lidocaine, dexmedetomidine, and intrathecal morphine on metastasis-related biomarkers and immune profiles in 114 adults undergoing colorectal cancer surgery. The study found that at 1 hour postoperatively, MMP-9 levels were significantly higher in the lidocaine group compared to both the dexmedetomidine and intrathecal morphine groups, indicating differential impacts on tumor progression pathways.
Key findings
- MMP-9 was higher in the lidocaine group than in the dexmedetomidine group (P = .009).
- Dexmedetomidine increased CD73 + CD8 + T cells compared to lidocaine (P = .050).
- Intrathecal morphine provided lower dynamic pain scores than the other groups.
- Rescue antiemetic use was less frequent in the dexmedetomidine group.
Why it matters
Understanding how different anesthetic adjuvants affect immune responses and biomarkers related to metastasis can inform multimodal analgesia strategies in colorectal cancer surgery, potentially influencing patient outcomes and long-term oncologic results.